Bollu, Lakshmi Reddy
Shepherd, Jonathan
Zhao, Dekuang
Ma, Yanxia
Tahaney, William http://orcid.org/0000-0002-7302-3161
Speers, Corey http://orcid.org/0000-0002-2362-2860
Mazumdar, Abhijit
Mills, Gordon B.
Brown, Powel H.
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (P30CA016672, P30CA016672)
Susan G. Komen for the Cure, Komen Wyoming Affiliate (KG081694)
Susan G. Komen (9SAB12-00006, SAC110052)
Breast Cancer Research Foundation (BCRF‐18-110)
Article History
Received: 28 March 2019
Accepted: 3 December 2019
First Online: 3 January 2020
Competing interests
: P.H.B. served as a Scientific Advisory Board Member for the Susan G. Komen for the Cure Foundation (until 2017) and is a holder of GeneTex stock (<1% of the total company stock); neither of these relate to this publication. G.B.M. is on advisory boards with AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMET, Ionis, Medimmune, Nuevolution, Pfizer, Precision Medicine, Signalchem Lifesciences, Symphogen, Takeda/Millennium Pharmaceuticals, and Tarveda; has stock options with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindle Top Ventures, and Tarveda; has sponsored research from Abbvie, Adelson Medical Research Foundation, AstraZeneca, Breast Cancer Research Foundation, Critical Outcomes Technology, Illumina, Ionis, Immunomet, Karus Therapeutics, Komen Research Foundation, Pfizer, Nanostring, Takeda/Millennium Pharmaceuticals, and Tesaro; and has licensed technology to Nanostring and Myriad Genetics. All remaining authors declare no actual, potential, or perceived conflict of interest that would prejudice the impartiality of this article.